NARCOLEPSY — GENETIC TESTING

Narcolepsy Genetic Testing — HLA-DQB1*06:02 is present in >98% of narcolepsy type 1 cases, making it the strongest HLA-disease association known and a powerful tool for diagnostic evaluation and exclusion.

Whole genome sequencing determines HLA-DQB1*06:02 status and evaluates additional narcolepsy susceptibility genes — providing the genetic component of narcolepsy diagnostic workup.

HLA-DQB1
TRA
TNFSF4
HCRTR2

About this condition

Narcolepsy — Genetic Testing

Narcolepsy type 1 (with cataplexy) is caused by autoimmune destruction of orexin/hypocretin-producing neurons in the hypothalamus. HLA-DQB1*06:02 is present in >98% of narcolepsy type 1 patients versus ~25% of the general population — the strongest known HLA-disease association. While carrying DQB1*06:02 is necessary but not sufficient (only ~1 in 500-1,000 carriers develops narcolepsy), its absence virtually excludes narcolepsy type 1.

The clinical utility of HLA-DQB1*06:02 testing is primarily diagnostic: in a patient with excessive daytime sleepiness, the ABSENCE of DQB1*06:02 makes narcolepsy type 1 extremely unlikely, redirecting the workup toward sleep apnea, idiopathic hypersomnia, or other causes. Its PRESENCE supports pursuing confirmatory testing (multiple sleep latency test, CSF orexin measurement).

Additional narcolepsy susceptibility genes include T-cell receptor alpha locus (TRA), TNFSF4 (OX40L), IL10RB, ZNF365, and P2RY11 — supporting the autoimmune model. Orexin receptor gene variants (HCRTR2) rarely cause familial narcolepsy in a non-HLA-dependent pattern.

HLA-DQB1*06:02 absence virtually EXCLUDES narcolepsy type 1. In a patient with sleepiness, negative DQB1*06:02 means the workup should focus on sleep apnea or idiopathic hypersomnia rather than narcolepsy.

Gene locus: HLA-DQB1 (6p21.32), TRA (14q11.2), TNFSF4 (1q25.1), HCRTR2 (6p12.1)

HLA-DQB1*06:02 is the strongest HLA-disease association known. WGS provides definitive HLA typing — both for narcolepsy diagnostic support and for the many other HLA-disease associations across autoimmune conditions.

DQB1*06:02 absence redirects the diagnostic workup — saving patients from unnecessary sleep studies

If HLA-DQB1*06:02 is absent, narcolepsy type 1 is virtually excluded. This can prevent unnecessary multiple sleep latency tests, lumbar punctures for CSF orexin, and years of diagnostic uncertainty. The workup is redirected toward idiopathic hypersomnia or other sleep-wake disorders.

Narcolepsy diagnosis opens targeted treatment options — pitolisant, solriamfetol, and sodium oxybate

Confirmed narcolepsy type 1 opens access to targeted treatments: sodium oxybate (Xyrem, both sleepiness and cataplexy), pitolisant (histamine H3 inverse agonist), solriamfetol (DNRI for sleepiness), and methylphenidate/modafinil. Genetic confirmation supporting the diagnosis ensures appropriate treatment rather than empirical stimulant therapy.

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks

Get my Genome Test